Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression.
Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with psychological support.
Egypt faces increasing difficulties in ensuring the availability of sufficient water resources that meet high-quality and acceptable standards. Factors including population growth, economic expansion, and various human activities collectively contribute to the degradation of surface water characteristics. The primary objective of this research is to evaluate the current condition of Idku Lake and propose viable solutions to alleviate the effects of pollution on the lake.
View Article and Find Full Text PDF